A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms.
The present study describes the effects of a commercially available genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) on clinical, pathological and virological features in three multi-site farms suffering from postweaning multisystemic wasting syndrome (PMWS). The vaccine product was able to reduce clinical signs, PCV2 viral load in lymphoid organs and/or sera, and overall mortality in nurseries and fattening units. This is the first time in which is shown that a PCV2 vaccine is able to decrease specifically PMWS-associated mortality. Another novelty of this study is the assessment of PMWS-like histological lesions in a large number of vaccinated and non-vaccinated pigs under field conditions.
Centre de Recerca en Sanitat Animal, UAB-IRTA, Campus de la Universitat, Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain. joaquim.segales@uab.cat
J
J
Segalés
A
A
Urniza
A
A
Alegre
T
T
Bru
E
E
Crisci
M
M
Nofrarías
S
S
López-Soria
M
M
Balasch
M
M
Sibila
Z
Z
Xu
H-J
HJ
Chu
L
L
Fraile
J
J
Plana-Duran
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018173:Circoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D005818:Genetic Engineering; D008297:Male; D053570:Porcine Postweaning Multisystemic Wasting Syndrome / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D013552:Swine; D019562:Viral Load; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*
D000914:Antibodies, Viral; D004279:DNA, Viral; D014765:Viral Vaccines